Safety and Behavior of S. Aureus Immune Globulin Intravenous(Human), [Altastaph] in Patients With S. Aureus Bacteremia and Continuing Fever

Phase 1/2 Completed 40 enrolled Nabi Biopharmaceuticals

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Altastaph has been developed to help the removal of S. aureus from the bloodstream. The main objective of this study will be to test the safety and behavior of Altastaph in patients with S.aureus bacteremia and continuing fever

Timeline

Start: 2002-09
Primary completion: 2004-09
Completion: 2004-09

Publications

Rupp ME, Holley HP Jr, Lutz J, Dicpinigaitis PV, Woods CW, Levine DP, Veney N, Fowler VG Jr. Phase II, randomized, multicenter, double-blind, placebo-controlled trial of a polyclonal anti-Staphylococcus aureus capsular polysaccharide immune globulin in treatment of Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2007 Dec;51(12):4249-54. doi: 10.1128/AAC.00570-07. Epub 2007 Sep 24.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Altastaph	Protein / enzyme biologic	200 mg/kg	Intravenous

Safety and Behavior of S. Aureus Immune Globulin Intravenous(Human), [Altastaph] in Patients With S. Aureus Bacteremia and Continuing Fever

Summary

Timeline

Publications

Drugs

Indications